SBI Securities’s Acurx Pharmaceuticals ACXP Stock Holding History

SBI Securities’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$22	Sell	6 -7	-54%	-$20	﹤0.01%	3741
2025 Q4	$32	Hold	13	–	–	﹤0.01%	3673
2025 Q3	$56	Sell	13 -1	-7%	-$6	﹤0.01%	3677
2025 Q2	$145	Hold	14	–	–	﹤0.01%	3418
2025 Q1	$111	Hold	14	–	–	﹤0.01%	3409
2024 Q4	$220	Buy	+14	New	+$422	﹤0.01%	3203

Other funds holding ACXP

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

PFS

Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return

SBI Securities's ACXP Position: Q1 2026 in Review

SBI Securities reduced its Acurx Pharmaceuticals (ACXP) stake by 54% in Q1 2026, selling an estimated $20 and leaving 6 shares worth $22. The position accounts for ﹤0.01% of the portfolio, ranked #3741.

SBI Securities first reported a position in ACXP in Q4 2024 and has held it in 6 quarters since. The position peaked at $220 in Q4 2024. 21 funds tracked by Wall St. Rank hold ACXP as of Q1 2026.

SBI Securities held 6 shares of Acurx Pharmaceuticals worth $22 as of Q1 2026.
SBI Securities sold 7 Acurx Pharmaceuticals shares in Q1 2026, an estimated $20.
Acurx Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #3741 holding.
SBI Securities first reported a position in Acurx Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
SBI Securities's Acurx Pharmaceuticals position peaked at $220 in Q4 2024.
21 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.